Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Lincoln Pharmaceuticals Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
The investor presentation does not provide any revenue, sales, or volume figures for the quarter due to the server being temporarily unavailable on page 2. EBITDA: ₹26.6 crore, up 41% year-on-year - Operating Margin: 19.3%, up by 320 basis points (bps) year-on-year - Profit after Tax (PAT): ₹15.7 crore, up 36% year-on-year - Margin Outlook: The presentation explicitly states a focus on sustaining and improving margins going forward, aiming to maintain operating margin expansion driven by cost optimization and profitable product mix.
From Lincoln Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
Profitability & Margins
See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹187 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lincoln Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…
- SMS Pharmaceuticals Ltd (Q1 FY27)
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…
Frequently Asked Questions
What were Lincoln Pharmaceuticals Ltd Q1 FY27 results?
The investor presentation does not provide any revenue, sales, or volume figures for the quarter due to the server being temporarily unavailable on page 2. EBITDA: ₹26.6 crore, up 41% year-on-year - Operating Margin: 19.3%, up by 320 basis points (bps) year-on-year - Profit after Tax (PAT): ₹15.7 crore, up 36% year-on-year - Margin Outlook: The presentation explicitly states a focus on sustaining and improving margins going forward, aiming to maintain operating margin expansion driven by cost optimization and profitable product mix.
What is Lincoln Pharmaceuticals Ltd share price analysis?
Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 12.6 with a market cap of ₹1,212 Cr. Investors should review the full earnings analysis for detailed insights.
Is Lincoln Pharmaceuticals Ltd planning capital expenditure?
The investor presentation does not provide any specific information on capex, capacity expansion, or new plant/project details, including amounts, status, or timelines.
Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.